No title
Background Previous trials of interferon in multiple sclerosis (MS) have shown efficacy, but the degree of clinical benefit remains uncertain, and the optimum dose is not known. We undertook a double-blind, placebo-controlled study in relapsing/remitting MS to investigate the effects of subcutaneous interferon -1a. Methods 560 patients with Kurtzke expanded disability status scale (EDSS) scores o
